News

In The News ADVI Health estimates year one of the Most Favored Nations (MFN) Model could cut Part B drug payments by $4.2 Billion.
In The News Lindsay Bealor Greenleaf discusses the health care policy outlook under a likely split Congress and Biden Administration with Morning Consult
In The News ADVI VP Lindsay Bealor Greenleaf explained to Fierce Healthcare about drug policy expectations following the Presidential election
In The News ADVI VP Lindsay Bealor Greenleaf weighs in on how the Presidential election’s results could shape the future of health policy
In The News LUNGevity Foundation Welcomes Michael Kolodziej, MD, to Its Board of Directors
In The News ADVI’s Kip Piper sat down with Modern Healthcare to weigh in on how the drug importation final rule would impact Medicaid rebates
In The News Our VP of Policy Lindsay Bealor Greenleaf weighed in on the possible unintended consequences of the int’l reference pricing Executive Order with CNBC
In The News Lindsay Bealor Greenleaf, VP of Policy at ADVI, recently shared her thoughts with Bloomberg Law about the impacts of an appeals court decision to uphold reimbursement cuts for hospitals receiving drugs under the 340B discount program
In The News ADVI Director, Becca Davison, sat down with Modern Healthcare to discuss the lack of transparency surrounding 340B and how manufacturers are engaging with entities utilizing the program